Key Dates

Related Announcements

PAR-20-180 - Identifying Innovative Mechanisms or Interventions that Target Multimorbidity and Its Consequences (R01 Clinical Trial Optional)

Issued by

Office of Research on Women's Health (ORWH)

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Purpose

The purpose of this notice is to inform potential applicants that the Office of Research on Women's Health (ORWH) and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) will participate, effective immediately, in PAR-20-180, "Identifying Innovative Mechanisms or Interventions that Target Multimorbidity and Its Consequences (R01 Clinical Trial Optional)".

The following text has been added to reflect ORWH's and NICHD's participation in this FOA.
 

Part 1. Overview Information

Components of Participating Organizations

Office of Research on Women’s Health (ORWH)

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
 

Catalog of Federal Domestic Assistance (CFDA) Numbers

93.313, 93.865
 

Part 2. Section I. Funding Opportunity Description

Priority Areas:

Office of Research on Women's Health (ORWH)

ORWH is part of the Office of the Director of NIH and works in partnership with the 27 NIH Institutes and Centers to ensure that women's health research is part of the scientific framework at the NIH and throughout the scientific community.

The 2019-2023 Trans-NIH Strategic Plan for Women's Health Research includes goals and objectives that aim to increase and improve women's health research supported by NIH. Goal two of the strategic plan is to "develop methods and leverage data sources to consider sex and gender influences that enhance research for women's health." To achieve this goal, in part, the ORWH is interested in research that could have a significant impact on understanding and addressing the multimorbidity or multiple chronic conditions (MCCs) among women.

Areas of research interest include, but are not limited to:

• Examining the role of sex and gender in pathways to multiple morbidities.
• Studying the mechanisms of multimorbidity through heritable influences.
• Identifying or modeling clinically meaningful phenotypes to elucidate mechanisms underlying the manifestation and impact of the phenotype on/in multiple systems.
• Conducting multidisciplinary studies that advance integrative, sex phenotyping to guide translational research questions of MCCs and create more innovative and precise use of existing therapeutic tools.
• Conducting longitudinal studies of normative development on multiple chronic comorbidities in special populations of women such as racial and ethnic minority populations of women, women with complex health needs, women residing in rural or underserved urban areas, women in migrant and immigrant populations, women experiencing homelessness or living in overcrowded congregate housing, or women involved with the criminal system (incarcerated or under community supervision).
   

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NICHD invites applications that respond to the priority areas articulated in the NICHD Strategic Plan 2020. In particular, NICHD welcomes applications through this funding opportunity that directly address the following areas of interest:

• Studies of cellular, molecular or physiologic mechanisms of MCCs that are specific or unique to NICHD priority populations, including:
   

• Infants, children and adolescents
• Individuals with intellectual and developmental disabilities
• Individuals with specific learning disorders
• Individuals with physical disabilities
• Pregnant, lactating and postpartum women
   

NICHD has a particular interest in supporting studies of polypharmacy in NICHD priority populations with MCCs. Such studies should provide insight into potential pharmacokinetic and/or pharmacodynamic medication interactions among individuals in NICHD priority populations who are prescribed multiple medications for their MCCs. Studies should focus on characteristics that are unique to the priority population being studied and should have the potential to inform future interventional studies to optimize the safety and efficacy of pharmacotherapy for patients with MCCs. For polypharmacy studies with a focus on individuals with physical disabilities, the project must have a clear impact on rehabilitation services.

Studies should also seek to identify common mechanisms that are potentially relevant to a range of conditions and diagnoses: NICHD will not support studies applicable only to a single group of related conditions or a single organ system.

• Studies of interventions to prevent or mitigate the consequences of MCCs in NICHD priority populations, including individuals who are also members of racially/ethnically diverse, sexual minority, and underserved/low-resource communities.
   

For this funding opportunity, NICHD will accept interventional studies only in the following areas:

• Studies of interventions to prevent or mitigate the impact of MCCs on maternal morbidity and mortality (defined as morbidity and mortality occurring during pregnancy or up to 1 year following delivery). Such interventions should consider both maternal and infant outcomes.
• Studies of interventions to prevent or mitigate MCCs emanating from the multiple organ dysfunction syndrome (MODS), independent of the etiology.
• Studies of interventions to improve the transition of children and adolescents with MCCs from adolescence to adulthood. Proposals specific to transition of health care as well as proposals looking more broadly at transition to adulthood and independent living among adolescents with MCCs are of interest. Studies of transition among adolescents with physical disabilities, intellectual disabilities, and/or specific learning disorders and co-occurring MCCs are of particular interest. All such proposals must be applicable to a range of conditions and diagnoses: NICHD will not accept proposals that are applicable only to a single group of related conditions or a single organ system.
   

Any proposed intervention study must use outcome measures shown to be valid in the target population being studied.

All other aspects of PAR-20-180 remain unchanged.

Inquiries

Please direct all inquiries to:

Rajasri Roy, Ph.D., M.P.H.

Office of Research on Women’s Health (ORWH)

Telephone: 301-451-0993

Email: rajasri.roy@nih.gov
 

Tracy King, M.D., M.P.H.

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Telephone: 301-402-1822

Email: tracy.king@nih.gov